A biomarker and therapeutical target in immune thrombocytopenia: TNF receptor-associated factor 6. (17th December 2018)

• Record Type: Journal Article
• Authors: Asoglu, Veysi; Umit, Elif G; Demir, Muzaffer
• Is Part Of: Biomarkers in medicine. Volume 13:Number 1(2019)
• Page Start: 27
• Page End: 31
• Publication Date: 2018-12-17
• Subjects: immune thrombocytopenia -- immunity -- TRAF6; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm-2018-0236
• Languages: English
• ISSNs: 1752-0363

Abstract

Background: Immune thrombocytopenia (ITP) is an acquired disease characterized by various pathogenetic mechanisms. We aimed to evaluate the value of TRAF6 as a biomarker of pathogenesis in ITP.Methods: 85 newly diagnosed ITP patients and 85 controls were included.Results: In the patient group, mean TRAF6 level was 2348 pg/ml and in the control group, TRAF6 level was 25.57 pg/ml. In corticosteroid-responding patients, TRAF6 levels were lower than nonresponding patients.Discussion: TRAF6 levels were observed to be higher than healthy controls, which suggest a solid relation with ITP pathogenesis. The observation that in patients who present with high TRAF6 levels, there was a significant corticosteroid refractoriness and responsiveness.